Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy

Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations

Deborah J. Thompson, Richard S. Houlston, Catherine Phelan · Nature Genetics · 2002 · 1.1K citations · Full text

Breast Oncology, Medicine, Brca2 Mutations +7

Contralateral Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Kelly Metcalfe, Henry T. Lynch, Parviz Ghadirian et al. · Journal of Clinical Oncology · 2004 · 616 citations

CHEK2*1100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 Studies

The American Journal of Human Genetics · 2004 · 471 citations · Full text

Breast Oncology, Oncology, Cancer Epidemiology +9

Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in <i>BRCA1/2</i>-Associated Stage I/II Breast Cancer

Lori J. Pierce, Albert M. Levin, Timothy R. Rebbeck et al. · Journal of Clinical Oncology · 2006 · 335 citations

Contralateral Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Monika Graeser, Christoph Engel, Kerstin Rhiem et al. · Journal of Clinical Oncology · 2009 · 309 citations